FDA puts business interests above public health, congressman charges
This article was originally published in The Silver Sheet
Executive Summary
Rep. Henry Waxman, D-Calif., is challenging FDA's priorities for writing rules and guidances, saying the agency appears to be more interested in loosening marketing restrictions and reducing product liability for device and drug manufacturers than in protecting public health. Prompting Waxman's ire and an investigation by his House Oversight and Government Reform Committee is an internal FDA e-mail listing eight regulation and guidance priorities compiled in June 2007 by Scott Danzis, special assistant to then-Chief Counsel Sheldon Bradshaw. "All appear to prioritize industry desires over consumer protection," Waxman writes in a Sept. 17 letter to FDA Commissioner Andrew von Eschenbach. The congressman wants to know "why FDA would need to act on each initiative at this point in time, given the other public health challenges and priorities you have identified," including findings by the FDA Science Board that the agency neglects facility inspections, oversees a broken import system and needs more scientists who understand emerging technologies ("The Silver Sheet" December 2007)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.